Literature DB >> 19671658

Clinical and molecular characterizations of novel POU3F4 mutations reveal that DFN3 is due to null function of POU3F4 protein.

Hee Keun Lee1, Mee Hyun Song, Myengmo Kang, Jung Tae Lee, Kyoung-Ah Kong, Su-Jin Choi, Kyu Yup Lee, Hanka Venselaar, Gert Vriend, Won-Sang Lee, Hong-Joon Park, Taeg Kyu Kwon, Jinwoong Bok, Un-Kyung Kim.   

Abstract

X-linked deafness type 3 (DFN3), the most prevalent X-linked form of hereditary deafness, is caused by mutations in the POU3F4 locus, which encodes a member of the POU family of transcription factors. Despite numerous reports on clinical evaluations and genetic analyses describing novel POU3F4 mutations, little is known about how such mutations affect normal functions of the POU3F4 protein and cause inner ear malformations and deafness. Here we describe three novel mutations of the POU3F4 gene and their clinical characterizations in three Korean families carrying deafness segregating at the DFN3 locus. The three mutations cause a substitution (p.Arg329Pro) or a deletion (p.Ser310del) of highly conserved amino acid residues in the POU homeodomain or a truncation that eliminates both DNA-binding domains (p.Ala116fs). In an attempt to better understand the molecular mechanisms underlying their inner ear defects, we examined the behavior of the normal and mutant forms of the POU3F4 protein in C3H/10T1/2 mesodermal cells. Protein modeling as well as in vitro assays demonstrated that these mutations are detrimental to the tertiary structure of the POU3F4 protein and severely affect its ability to bind DNA. All three mutated POU3F4 proteins failed to transactivate expression of a reporter gene. In addition, all three failed to inhibit the transcriptional activity of wild-type proteins when both wild-type and mutant proteins were coexpressed. Since most of the mutations reported for DFN3 thus far are associated with regions that encode the DNA binding domains of POU3F4, our results strongly suggest that the deafness in DFN3 patients is largely due to the null function of POU3F4.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671658     DOI: 10.1152/physiolgenomics.00100.2009

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  14 in total

1.  De novo mutation in X-linked hearing loss-associated POU3F4 in a sporadic case of congenital hearing loss.

Authors:  Hideaki Moteki; A Eliot Shearer; Shuji Izumi; Yamato Kubota; Hela Azaiez; Kevin T Booth; Christina M Sloan; Diana L Kolbe; Richard J H Smith; Shin-Ichi Usami
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-03-19       Impact factor: 1.547

2.  Spectrum of DNA variants for non-syndromic deafness in a large cohort from multiple continents.

Authors:  Denise Yan; Demet Tekin; Guney Bademci; Joseph Foster; F Basak Cengiz; Abhiraami Kannan-Sundhari; Shengru Guo; Rahul Mittal; Bing Zou; Mhamed Grati; Rosemary I Kabahuma; Mohan Kameswaran; Taye J Lasisi; Waheed A Adedeji; Akeem O Lasisi; Ibis Menendez; Marianna Herrera; Claudia Carranza; Reza Maroofian; Andrew H Crosby; Mariem Bensaid; Saber Masmoudi; Mahdiyeh Behnam; Majid Mojarrad; Yong Feng; Duygu Duman; Alex M Mawla; Alex S Nord; Susan H Blanton; Xue Z Liu; Mustafa Tekin
Journal:  Hum Genet       Date:  2016-06-25       Impact factor: 4.132

3.  Cytoplasmic mislocalization of POU3F4 due to novel mutations leads to deafness in humans and mice.

Authors:  Thomas Parzefall; Shaked Shivatzki; Danielle R Lenz; Birgit Rathkolb; Kathy Ushakov; Daphne Karfunkel; Yisgav Shapira; Michael Wolf; Manuela Mohr; Eckhard Wolf; Sibylle Sabrautzki; Martin Hrabé de Angelis; Moshe Frydman; Zippora Brownstein; Karen B Avraham
Journal:  Hum Mutat       Date:  2013-05-08       Impact factor: 4.878

Review 4.  Octamer-binding transcription factors: genomics and functions.

Authors:  Feng-Qi Zhao
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

5.  A New Pathogenic Variant in POU3F4 Causing Deafness Due to an Incomplete Partition of the Cochlea Paved the Way for Innovative Surgery.

Authors:  Ahmet M Tekin; Marco Matulic; Wim Wuyts; Masoud Zoka Assadi; Griet Mertens; Vincent van Rompaey; Yongxin Li; Paul van de Heyning; Vedat Topsakal
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

6.  Novel domain-specific POU3F4 mutations are associated with X-linked deafness: examples from different populations.

Authors:  Guney Bademci; Akeem Lasisi; Kemal O Yariz; Paola Montenegro; Ibis Menendez; Rodrigo Vinueza; Rosario Paredes; Germania Moreta; Asli Subasioglu; Susan Blanton; Suat Fitoz; Armagan Incesulu; Levent Sennaroglu; Mustafa Tekin
Journal:  BMC Med Genet       Date:  2015-02-25       Impact factor: 2.103

7.  A POU3F4 Mutation Causes Nonsyndromic Hearing Loss in a Chinese X-linked Recessive Family.

Authors:  Wan Du; Ming-Kun Han; Da-Yong Wang; Bing Han; Liang Zong; Lan Lan; Ju Yang; Qi Shen; Lin-Yi Xie; Lan Yu; Jing Guan; Qiu-Ju Wang
Journal:  Chin Med J (Engl)       Date:  2017-01-05       Impact factor: 2.628

8.  Clinical and molecular characterization of POU3F4 mutations in multiple DFNX2 Chinese families.

Authors:  Yu Su; Xue Gao; Sha-Sha Huang; Jing-Ning Mao; Bang-Qing Huang; Jian-Dong Zhao; Dong-Yang Kang; Xin Zhang; Pu Dai
Journal:  BMC Med Genet       Date:  2018-09-04       Impact factor: 2.103

9.  SNP linkage analysis and whole exome sequencing identify a novel POU4F3 mutation in autosomal dominant late-onset nonsyndromic hearing loss (DFNA15).

Authors:  Hee-Jin Kim; Hong-Hee Won; Kyoung-Jin Park; Sung Hwa Hong; Chang-Seok Ki; Sang Sun Cho; Hanka Venselaar; Gert Vriend; Jong-Won Kim
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

10.  Novel and De Novo Mutations Extend Association of POU3F4 with Distinct Clinical and Radiological Phenotype of Hearing Loss.

Authors:  Agnieszka Pollak; Urszula Lechowicz; Anna Kędra; Piotr Stawiński; Małgorzata Rydzanicz; Mariusz Furmanek; Małgorzata Brzozowska; Maciej Mrówka; Henryk Skarżyński; Piotr H Skarżyński; Monika Ołdak; Rafał Płoski
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.